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consequences to the patient through toxic impurities and
microbial contamination.
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Idiopathic or Secondary?
I read with interest the clinical observation by Mohammadet al (1) of “idiopathic intracranial hypertension” asso-
ciated with the topical application of vitamin A. Whether
or not one has abandoned the term “idiopathic intracranial
hypertension” for the term “primary pseudotumor cerebri,”
as recommended by De Simone et al (2), it would seem
to me that this case does not fall under the rubric of
“idiopathic” as it has at least a presumed etiology, that
is, vitamin A, and would be better termed “secondary
pseudotumor cerebri.”
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Diagnosing Chronic Lymphocytic Leukemia
With Temporal Artery Biopsy
W e read with interest the report of Ghinai et al (1)documenting how the diagnosis of light-chain amy-
loidosis was established with temporal artery biopsy in a pa-
tient suspected of having giant cell arteritis (GCA). We
would like to share our experience with a patient in whom
temporal artery biopsy ultimately led the diagnosis of
chronic lymphocytic leukemia.
A 74-year-old man developed acute painless vision loss
in his left eye. On examination, visual acuity was 20/20,
right eye and 20/40, left eye with diminished color vision in
the left eye and a left relative afferent pupillary defect. The
remainder of the ophthalmic examination was normal.
The patient's blood pressure was 123/86 mm Hg. Normal
laboratory testing including erythrocyte sedimentation rate
(4 mm/h), platelet count, glucose, cholesterol, and triglycerides.
Leukocyte count was 12.6 · 109 cells/L (normal range: 3.5 2
10.0 · 109 cells/L). Echocardiography and ultrasonography of
the carotid arteries were unremarkable.
Two months later, the patient complained of visual ﬁeld
loss in the right eye although visual ﬁeld testing was
unremarkable in that eye. There was an inferior altitudinal
defect in the left eye.
Six months after his initial visual complaints, the patient
reported acute, painless loss of vision in his right eye. Acuity
was counting ﬁngers, right eye and 20/30, left eye with
a right relative afferent pupillary defect. The right fundus
was normal and there was mild left optic disc pallor. The
right visual ﬁeld demonstrated central and inferior loss,
whereas the left ﬁeld was normal. Repeat testing including
erythrocyte sedimentation rate, C-reactive protein, and
platelet count was normal. A temporal artery biopsy was
performed. There were no ﬁndings suggestive of GCA but,
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within the surrounding tissue, lymphocyte aggregates were
seen (Fig. 1).
Additional testing revealed a leukocytosis of 27 · 109
cells/L. Flow cytometry showed a monoclonal B-cell pop-
ulation of 44% which was kappa light chain positive and
CD5, CD19, CD20, and CD23 positive. The immuno-
globulin heavy chain gene mutation status was not mutated;
11q and 17p deletions were not found. Diagnosis of chronic
lymphocytic leukemia (Rai stage II) was made.
Treatment was not begun because the patient did not meet
the criteria for active disease (2). However, because of recurrent
episodes of decreased vision in each eye, he was prescribed
prednisone 60 mg a day for 7 days, which lead to subjective
improvement in vision. Because the possible association of eye
symptoms with chronic lymphocytic leukemia was present,
and no other underlying causes were found, the patient was
placed on a regimen of rituximab, chlorambucil, and
prednisone each 28 days. After 6 monthly cycles, the patient
was in full remission, and after 8 cycles, his hematologist
switched him to rituximab maintenance monotherapy. The
patient's leukocyte count normalized to 4.4 · 109 cells/L, and
his visual acuity stabilized at 20/40, right eye and 20/20, left
eye. Visual function has remained stable during follow-up.
Although the precise cause of our patient's bilateral optic
neuropathy is uncertain, possibilities include vaso-occlusion or
paraneoplastic syndrome due to chronic lymphocytic leukemia.
Neither our clinical examination nor neuroimaging suggested
leukemic inﬁltration of the optic nerves. During our patient's
clinical course, GCA was in the differential diagnosis and
a temporal artery biopsy was performed. It was the ﬁnding
of perivascular lymphocytes on the biopsy specimen that
prompted us to pursue a hematologic evaluation, and arrive
at the correct diagnosis of chronic lymphocytic leukemia.
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The 14th Hoyt Lecture Ischemic Optic
Neuropathy: The Evolving Proﬁle,
1966–2015: Comment
I read with interest the Hoyt Lecture by Arnold (1) deal-ing with nonarteritic anterior ischemic optic neuropathy
(NAION). The observation of a small cup-to-disc ratio in
these patients was made by William F. Hoyt, but Arnold
erroneously attributed this to Sohan Singh Hayreh from an
article discussing the development of disc cupping after an
attack of arteritic AION instead (reference 17 in Arnold's
article). Yet, Bill Hoyt was the ﬁrst to recognize this
disc morphology in patients with NAION—what was
FIG. 1. Temporal artery biopsy shows no signs of giant cell
arteritis. An aggregate of lymphocytes (arrow) is seen in the
adventitia (hematoxylin and eosin, ·100).
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